At a glance
- Originator Amgen
- Class Small molecules
- Mechanism of Action Prostaglandin D2 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Allergic rhinitis; Asthma
Most Recent Events
- 28 Sep 2004 Preclinical trials in Allergic rhinitis in USA (PO)
- 28 Sep 2004 Preclinical trials in Asthma in USA (PO)